Farmaceutica REMEDIA Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Farmaceutica REMEDIA.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Consumer Retailing earnings growth	9.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

We Like These Underlying Return On Capital Trends At Farmaceutica REMEDIA (BVB:RMAH)

Mar 23

Does Farmaceutica REMEDIA (BVB:RMAH) Deserve A Spot On Your Watchlist?

Feb 16

Is There More To The Story Than Farmaceutica REMEDIA's (BVB:RMAH) Earnings Growth?

Jan 15

Is Farmaceutica REMEDIA S.A.'s (BVB:RMAH) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 16

Should You Invest In Farmaceutica REMEDIA (BVB:RMAH)?

Nov 18

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Farmaceutica REMEDIA has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

BVB:RMAH - Analysts future estimates and past financials data (RON Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	593	7	22	23	N/A
9/30/2023	567	7	0	1	N/A
6/30/2023	559	6	10	10	N/A
3/31/2023	554	6	0	0	N/A
12/31/2022	536	6	-2	-2	N/A
9/30/2022	523	6	16	16	N/A
6/30/2022	518	7	2	2	N/A
3/31/2022	490	7	5	5	N/A
12/31/2021	477	7	3	3	N/A
9/30/2021	453	7	-17	-17	N/A
6/30/2021	439	43	-5	-5	N/A
3/31/2021	433	41	-16	-16	N/A
12/31/2020	441	38	-14	-14	N/A
9/30/2020	452	37	9	10	N/A
6/30/2020	457	-1	2	3	N/A
3/31/2020	459	1	N/A	N/A	N/A
12/31/2019	446	2	4	5	N/A
9/30/2019	457	2	-18	-17	N/A
6/30/2019	464	3	-8	-7	N/A
3/31/2019	470	2	N/A	N/A	N/A
12/31/2018	464	3	-7	-6	N/A
9/30/2018	439	3	N/A	N/A	N/A
6/30/2018	404	5	-1	0	N/A
3/31/2018	376	5	N/A	N/A	N/A
12/31/2017	351	4	-10	-9	N/A
9/30/2017	326	4	N/A	N/A	N/A
6/30/2017	306	2	N/A	-2	N/A
3/31/2017	280	2	N/A	N/A	N/A
12/31/2016	255	1	N/A	0	N/A
9/30/2016	238	1	N/A	N/A	N/A
6/30/2016	233	1	N/A	6	N/A
3/31/2016	228	0	N/A	N/A	N/A
12/31/2015	240	1	N/A	11	N/A
9/30/2015	247	1	N/A	N/A	N/A
6/30/2015	242	2	N/A	N/A	N/A
3/31/2015	247	3	N/A	N/A	N/A
12/31/2014	248	3	N/A	-1	N/A
9/30/2014	238	4	N/A	N/A	N/A
6/30/2014	237	3	N/A	N/A	N/A
3/31/2014	241	3	N/A	N/A	N/A
12/31/2013	238	3	N/A	8	N/A
9/30/2013	244	3	N/A	N/A	N/A
6/30/2013	251	3	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RMAH's forecast earnings growth is above the savings rate (6.2%).

Earnings vs Market: Insufficient data to determine if RMAH's earnings are forecast to grow faster than the RO market

High Growth Earnings: Insufficient data to determine if RMAH's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RMAH's revenue is forecast to grow faster than the RO market.

High Growth Revenue: Insufficient data to determine if RMAH's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RMAH's Return on Equity is forecast to be high in 3 years time

Farmaceutica REMEDIA Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Now 21% overvalued

Full year 2023 earnings released: EPS: RON0.075 (vs RON0.061 in FY 2022)

Now 20% overvalued

Farmaceutica REMEDIA S.A., Annual General Meeting, Apr 25, 2024

Third quarter 2023 earnings released: EPS: RON0.023 (vs RON0.012 in 3Q 2022)

Upcoming dividend of RON0.05 per share at 7.0% yield

Returns At Farmaceutica REMEDIA (BVB:RMAH) Are On The Way Up

Less than half of directors are independent

Now 23% undervalued after recent price drop

Upcoming dividend of RON0.05 per share

Farmaceutica REMEDIA S.A. to Report First Half, 2022 Results on Aug 11, 2022

Less than half of directors are independent

Full year 2021 earnings released: EPS: RON0.076 (vs RON0.36 in FY 2020)

Farmaceutica REMEDIA's (BVB:RMAH) Returns On Capital Are Heading Higher

Second quarter 2021 earnings released

Returns Are Gaining Momentum At Farmaceutica REMEDIA (BVB:RMAH)

Inaugural dividend of RON0.15 per share

Full year 2020 earnings released: EPS RON0.36 (vs RON0.023 in FY 2019)

We Like These Underlying Return On Capital Trends At Farmaceutica REMEDIA (BVB:RMAH)

New 90-day high: RON0.78

Does Farmaceutica REMEDIA (BVB:RMAH) Deserve A Spot On Your Watchlist?

New 90-day high: RON0.69

Is There More To The Story Than Farmaceutica REMEDIA's (BVB:RMAH) Earnings Growth?

Farmaceutica REMEDIA S.A. to Report First Half, 2021 Results on Aug 12, 2021

New 90-day high: RON0.65

Is Farmaceutica REMEDIA S.A.'s (BVB:RMAH) Recent Performance Tethered To Its Attractive Financial Prospects?

Should You Invest In Farmaceutica REMEDIA (BVB:RMAH)?

Third quarter 2020 earnings released: EPS RON0.36

New 90-day high: RON0.58

New 90-day high - RON0.54

Help Net Farma S.A. agreed to acquire 63 Pharmacies from Farmaceutica REMEDIA S.A. (BVB:RMAH).

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies